Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCLAT1 | Q6UWP7 | 3/20 | 0.45 |
| ▸ | BRAF | P15056 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641998 | 0.90 | LCLAT1 (0.46) | LCLAT1BRAFEGFRMAPTLMNA | |
| SCHEMBL1640608 | 0.90 | BRAF (0.47) | LCLAT1BRAFEGFRMAPTLMNA | |
| SCHEMBL1641904 | 0.88 | BRAF (0.51) | BRAFEGFRMAPTCDK4CDK2 | |
| SCHEMBL1642305 | 0.86 | LCLAT1 (0.43) | LCLAT1BRAFEGFRMAPTLMNA | |
| SCHEMBL1642023 | 0.86 | LCLAT1 (0.47) | LCLAT1BRAFEGFRMAPTLMNA | |
| SCHEMBL3422428 | 0.85 | MAPK14 (0.48) | MAPTCDK4CDK2MAPK14TP53 | |
| SCHEMBL1640619 | 0.82 | LCLAT1 (0.49) | LCLAT1BRAFEGFRMAPTLMNA | |
| SCHEMBL1640567 | 0.79 | SLC2A1 (0.49) | BRAFEGFRCDK4CDK2 | |
| SCHEMBL12726655 | 0.79 | BTK (0.42) | BRAFMAPTCDK4CDK2MAPK14 | |
| SCHEMBL1640498 | 0.78 | BRAF (0.49) | BRAFEGFRMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2231625-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | LCLAT1 2338/4885BRAF 151/4885EGFR 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.